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Budd-Chiari syndrome (BCS) is a rare clinical condition resulting from obstruction of the hepatic venous outflow tract anywhere from the hepatic venules to the right atrium, including the small and large hepatic veins (HVs) and the inferior vena cava (IVC).
(1) Most cases of BCS in the Western world result from venous thrombosis that leads to diffuse obliteration of the veins, whereas in Asia the most common cause is IVC and/or HV obstruction due to membranous webs. (2) Clinically, most patients have evidence of portosystemic collaterals with an enlarged caudate lobe at presentation due to incomplete occlusion of the 3 main HVs. Most Western BCS patients have evidence of 1 or more underlying hypercoagulable states, most commonly polycythemia vera (PCV). (3) Acute liver failure (ALF) is traditionally defined as coagulopathy and altered mental status occurring within 26 weeks of onset, although most cases evolve over 1-3 weeks. Most cases of BCS present in subacute fashion, that is, over several weeks, not days due to partial occlusion of 1 or more of the HVs with increased return of intrahepatic blood via small perforating veins in the caudate lobe that drain directly into the vena cava or portosystemic collaterals that divert portal flow away from the liver.
(1) When the 3 main HVs draining the liver simultaneously clot, there can be diffuse and severe intrahepatic ischemia with massive necrosis and resultant ALF and inadequate time for collaterals to Abbreviations: ALF, acute liver failure; ALFSG, Acute Liver Failure Study Group; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCS, Budd-Chiari syndrome; CML, chronic myeloid leukemia; CT, computed tomography; HD, hemodialysis; HV, hepatic vein; INR, international normalized ratio; IVC, inferior vena cava; MELD, Model for End-Stage Liver Disease; MRI, magnetic resonance imaging; MOF, multiorgan failure; OCP, oral contraceptive; PCV, polycythemia vera; PNH, paroxysmal nocturnal hemoglobinuria; RUQ, right upper quadrant; TBili, total bilirubin; TIPS, transjugular intrahepatic portosystemic shunt; US, ultrasound; VEN, venography; WBC, white blood cell.
develop. ALF is the rarest presentation of BCS, and BCS is one of the rarest etiologies of ALF. (4) BCS, in all of its presentations, is an orphan disease, with only a handful of clinical trials dedicated to its study. (5) The pathophysiology of ALF due to BCS likely differs from that of many other subacute causes of ALF, in that it has a very high mortality rate and relatively rapid clinical course, necessitating urgent determination and management of the underlying cause.
Historically, there have been multiple management options for BCS, including anticoagulation, thrombolysis, angioplasty, transjugular intrahepatic portosystemic shunt (TIPS), surgical portosystemic shunt, and orthotopic liver transplantation. For these reasons, it is worth seeking patterns in the clinical presentation and outcomes of ALF-BCS patients. However, ALF due to BCS (ALF-BCS) is very rare and has mainly been described in case reports. Although series of BCS patients have been published, nearly all of them studied all levels of severity of BCS together, without clearly defining the level of acuity or severity. (6) (7) (8) (9) The aim of this study is to describe the presenting laboratory and clinical features of 19 consecutive adults with ALF-BCS that were enrolled in the US Acute Liver Failure Study Group (ALFSG) over a 15-year period. We reviewed the presenting features, management, and short-term and longterm outcomes and compared them with the previously reported cases.
Patients and Methods

PATIENTS
To date, more than 2344 patients have been enrolled in the ALFSG registry from 1998 to 2015, all meeting standard criteria of hepatic encephalopathy and coagulopathy (international normalized ratio [INR] 1.5) after an acute illness. Per institutional review board guidelines, informed consent was obtained from next of kin prior to enrollment since all patients are, by definition, encephalopathic at the time of enrollment. This study was approved by the UT Southwestern institutional review board. Demographics, history, ALF etiology (based on diagnostic criteria used at all participating sites), physical findings, laboratory values, imaging and biopsy reports, and hospital course are recorded for each patient at the time of admission to the study. Also recorded are outcome data (death, liver transplantation, or survival) 3 weeks after admission to the study and, if available, at 1 and 2 years following admission.
LITERATURE REVIEW
We searched for English language case reports and series specifically devoted to BCS leading to ALF in the MEDLINE database from January 1998 to December 2015 using various combinations of 1 or more of the following text keywords: "fulminant," "Budd-Chiari," and "acute liver failure." The titles and (where available) abstracts of all search results were read. When a title or abstract suggested that the corresponding article described 1 or more ALF-BCS patients, the entire article was then read. Articles that were referenced within the main text of these articles as describing ALF-BCS patients were also reviewed. Only articles describing 1 or more ALF-BCS patients for whom the text explicitly made clear that our full definition of ALF was met were included in our analysis. Finally, we ensured that none of the published cases we found were also among the ones we found in the ALFSG database.
ANALYSIS
Data are reported as medians and ranges. Comparisons between continuous variables were performed with the Wilcoxon rank sum test, and categorical variables were analyzed with the chi-square test. All tests were 2-sided, and P values of <0.05 were considered statistically significant. STATA/SE 14.0 (StataCorp, College Station, TX) was used to perform all analyses.
Results
CLINICAL CHARACTERISTICS
From January 1, 1998 to December 1, 2015, 20 patients out of 2344 enrolled in the ALFSG registry during the study period were determined to have ALF secondary to BCS. From these 20, we selected 19 that were considered truly acute. The excluded patient had HV obstruction from a metastatic adenocarcinoma that evolved over a prolonged period of time. Overall, the patients were young (median age, 38 years; range, 19-59 years) and comprised of mostly Caucasian women (84%). PCV was the most commonly identified thrombophilic factor (37%), and 3 patients were presumed to be hypercoagulable based on estrogen use and history of prior clots. One patient had a confirmed homozygous Factor V Leiden mutation (Table 1) .
DIAGNOSTIC STUDIES
All patients underwent abdominal ultrasound (US) with Doppler analysis as part of their initial evaluation. Computed tomography (CT) or magnetic resonance imaging (MRI) was often used later in the hospital course to better define anatomy and/or extent of the clot burden. Notable findings on US or CT included presence of ascites, hepatomegaly, heterogeneous (or mottled on CT) hepatic parenchyma, caudate lobe hypertrophy, thickened gallbladder wall, and splenomegaly. Doppler US findings included IVC compression; no flow in or nonvisualization of the HVs; and slow, hepatofugal, or bidirectional flow in the portal or splenic veins. CT scans showed nonopacification of all of the HVs and/or IVC compression at the level of the caudate lobe. MRI findings were analogous to those on CT. There were no patients who underwent venography (VEN) without already having had evidence of venous occlusion on US, CT, or MRI. There were no venous collaterals seen by any modality. Likewise, there were no findings of diffuse liver atrophy or hepatic regenerative nodules as can be seen in chronic BCS patients with longstanding occlusion of 1 or more HVs. For the most part, routine diagnostic studies failed to reveal a cause for the BCS such as an unsuspected intrahepatic tumor or disease of the vena cava such as a membranous web or congenital anomalies. Of the 19, 12 patients underwent formal workup for coagulation abnormalities during their ALF hospitalization. Of interest, the aspartate aminotransferase (AST)-toalanine aminotransferase (ALT) ratio in this population exceeded 1 in 18/19 (95%) of patients. Liver biopsy was used sparingly in this population: 6 patients underwent biopsy, all showing severe centrilobular congestion and hepatocyte necrosis, without significant fibrosis.
TREATMENT AND OUTCOMES
A summary of each case is provided in Table 2 . Overall, anticoagulation was the first line of therapy with 71% of patients being treated on or shortly after admission with IV heparin. Patients who were anticoagulated were more likely to survive than those who were not. In fact, 100% of survivors were anticoagulated on or shortly after admission compared with 50% of patients who died (Table 1) . Furthermore, complications of bleeding were uncommon in this population despite usage of anticoagulation. Only 2 clinically relevant episodes were captured: 1 associated with TIPS and the other with the placement of an intracranial pressure monitor.
Various interventions were also employed in the management of BCS with varying success. The 2 patients who underwent surgical shunts both died. The 1 patient who underwent thrombolysis/angioplasty alone also died. The remaining cases of thrombolysis/angioplasty were done along with or followed by TIPS that was employed in 8 patients. Seven patients Overall, 8 (42%) patients survived their inpatient hospitalization. All 8 were alive at the time of followup (median, 4 months; range, 1-94 months). Of all laboratory parameters examined, elevated peak AST, peak ALT, and peak creatinine were associated with patient death. As previously mentioned, anticoagulation at the time of admission was a statistically significant predictor of survival. In comparing treatment modalities, there was no discernible survival benefit to TIPS or transplant in this small population. However, the majority of the survivors have been in the more modern era, with 7/8 survivors identified during the post-Model for End-Stage Liver Disease (MELD) era and 5 of those being enrolled after 2010. Though limited by the size of the patient population, the year of transplant was also a statistically significant predictor of survival (Table 1) .
LITERATURE REVIEW
We found 19 ALF-BCS cases published among 17 patient reports/series that considered all forms of BCS. (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) No patient series specifically focused on ALF-BCS and all were published prior to 2007. The characteristics of the 19 patients from the literature are presented in Table 3 . The most common etiology determined in published series was PCV (41% of patients). As with the ALFSG patients, the published cases variably featured imaging with US, CT, MRI, and VEN. Findings were analogous to those described for the ALFSG patients, with the exception that 2 of the patients (both with PCV) had venous collaterals around the thrombi visualized on MRI, CT, or VEN. Table 3 lists features of the clinical presentations, treatments, and outcomes of the patients from the literature, categorized by survival. None of the articles defined a 3-week study period, but we deduced the outcomes at this time point in order to compare them with the ALFSG patients. The results were analogous to those for ALFSG patients. Six of the 19 patients received only supportive treatment with anticoagulation. Only 2 of these 6 survived the initial hospital stay and were alive at 2 months and 1 year, respectively. Two of 19 received supportive treatment alone, without anticoagulation, and 3 received supportive treatment but with unknown anticoagulation status. All 5 of the latter died during the initial hospital stay. Only 1 patient each received thrombolysis (death on day 18 from gastrointestinal hemorrhage), angioplasty (death on day 11 from undocumented cause), and surgical shunts (in addition to TIPS; death on day 17 from multiorgan failure [MOF] ). Three of the 4 (75%) TIPS patients survived both the 3-week study period and their initial hospital stays, and these 3 patients were also the only 3 published cases of patients who received both TIPS and liver transplant. All 5 of the liver transplant patients (including the 3 who also received TIPS prior to liver transplant) survived at least a median of 3.5 months (range, 1-8 months). Complications were generally similar to the ones noted for the ALFSG cases, the most common being acute renal failure (6 patients; 35%).
Among the 19 literature cases reviewed, 8 (42%) patients died by the end of 3 weeks, 12 (63%) succumbed during their initial hospital stay, and 5 of the 17 (29%) patients for whom follow-up data were available survived at least a median of 4 months (range, 2-12 months). The most common cause of death among the 7 patients whose causes of death were specified was multiorgan failure (43%).
Discussion
Using the ALFSG study cohort, we have assembled the largest series of ALF from BCS reported in the literature. Overall, ALF from BCS is an extremely rare condition, accounting for <1% of patients in the ALFSG registry. Even physicians at tertiary transplant centers are likely to see this once in their careers, making the lessons of this case series particularly valuable.
The ALFSG patients had similar demographics and etiologies when compared with previously published cases of ALF-BCS and with BCS patients in general. (6, 7) Most were white females in their fourth to fifth decades, and the most common etiology was PCV. Most of the ALF-BCS patients in our series had 1 or more thrombophilic risk factors, as has been observed elsewhere for BCS in general.
The most common presenting symptoms and signs (abdominal pain, ascites, jaundice, lower-extremity edema, and malaise) in both the ALFSG and published cases were nonspecific, although the presence of pain and ascites are atypical for most forms of ALF. Regardless of presentation, a patient presenting with ALF should undergo US examination with Doppler imaging. US has become the mainstay of diagnosis, and a positive sonogram should be adequate to initiate anticoagulation. Confirmatory studies such as CT or MRI provide additional imaging which may help surgeons or interventional radiologists develop their treatment plan. Interestingly, laboratory values may provide an early clue to the diagnosis of ALF from BCS as the majority of these patients had an AST:ALT ratio >1. In fact, this pattern of injury, which is less common in ALF cases due to acetaminophen toxicity and viral hepatitis, (26, 27) was found in 95% of patients in this series. The peak AST and ALT were also some of the statistically significant predictors of survival in our series, providing a clear marker of the severity and/or acuity of the event. This is consistent with Rautou et al. who also found that peak ALT was associated with poor outcomes, supporting the idea that greater ischemia portends worse patient outcomes. (28) Higher peak creatinine level was also observed to be a significant predictor of poor outcome. However, total bilirubin (TBili) and peak INR were not. In fact, both MELD score and the King's College criteria for nonacetaminophen liver failure were not predictive of survival in these patients. This may be due to the fact the patients are uniformly ill but early anticoagulation and TIPS may offer therapeutic benefit which are not available to other etiologies of ALF. Therefore, these traditional scoring systems may not serve as an accurate predictor of survival, and clinicians should focus on encephalopathy and overall clinical trends when deciding if a patient is improving.
The survival of ALF-BCS patients has historically been poor. During the initial hospital stay, the survival of both ALFSG and previously published cases was between 37% and 40%, even with the availability of liver transplantation. These survival rates are much lower than the 5-year survival rates of BCS cases in general, which has been as high as 80% in recent cohorts, but is similar to other subacute presentations of ALF. (3) Closer examination reveals a more positive outlook when you focus on the modern era. With improved surgical techniques, critical care, widely available highquality US, and recognition that anticoagulation is safe and even required in these patients, survival seems to have improved. Though our case series is too small to draw definitive conclusions, the majority of survivors occurred after 2010 and year of transplant was a statistically significant predictor of survival on univariate analysis. Because of its rarity, ALF-BCS has seldom been examined carefully as a distinct entity. In the last decade, a stepwise algorithm, in order of increasing invasiveness, has emerged for BCS patients in general. (29) (30) (31) (32) On the basis of our review of this case series and the literature, we have proposed a similar algorithm for patients with ALF due to BCS (Fig. 1) . Despite the small sample size, there are some clear lessons that can be taken away from the present case series. Anticoagulation should be initiated as soon as the diagnosis of BCS is made. Surgical shunts have largely been replaced by TIPS. (31, 33) TIPS/angioplasty can be pursued early on while the underlying cause of BCS is being determined. This is consistent with Garcia-Pag an et al. (8) who found TIPS to be an effective treatment for BCS in a large series that included 9 patients with ALF.
Should malignancy that precludes transplant be found, then care appropriate to the patient's condition and prognosis can be implemented. A diagnosis of PCV or any myeloproliferative disorder does not preclude listing for transplantation and in these patients an evaluation of transplant candidacy should occur in parallel with anticoagulation and TIPS. Early initiation of anticoagulation and TIPS may then provide clinicians with a window of several days during which time assessment for clinical improvement can be made while the decision to list/transplant is undertaken. The INR may not be reliable depending on the method of anticoagulation; notably, both argatroban and Coumadin affect prothrombin time, making it difficult to judge improvement in hepatic function based on the INR value. Should the patient improve, transplant can be avoided. However, if no improvement is seen transplant remains a salvageable option. Similarly, if TIPS cannot be performed due to technical limitations, then liver transplant is an option if there are no other medical or social barriers. Regardless of intervention, anticoagulation should be continued as long as the patient does not suffer complications of bleeding that preclude ongoing therapy.
In conclusion, BCS is a very rare cause of ALF. Early anticoagulation followed by TIPS and/or liver transplant for ALF-BCS are likely the main modalities to be employed in the management of Western patients with this disease. Despite these technical advances, ALF-BCS still carries a very high mortality; we hope that our description of ALF-BCS will inspire larger, prospective studies to benefit these critically ill patients.
